The study drug is called acoramidis (AG10). It is a tablet, taken by mouth 2 times each day.
The study drug is investigational, which means it can only be used for research studies. It has not been approved by regulatory authorities like the Food and Drug Administration (FDA) or European Medicines Agency (EMA).
In people with ATTR-PN, a gene mutation causes the protein transthyretin (TTR) to become unstable and build up in the organs.
The ATTRibute-PN study is an open label study, which means all participants will receive the study drug.
Find a study clinic near you